BridgeBio Pharma (BBIO) Q3 2026 Earnings
Includes recognition of a one-time $75.0 million BEYONTTRA sales milestone from Bayer in license and services revenue; net loss attributable to common stockholders also reflects $26.3 million (26,293 thousand) of preferred stock dividends and accretion.
How Did BBIO Stock React to Q3 2026 Earnings?
Did BBIO Beat Earnings? Q3 2026 Results
Yes. BridgeBio Pharma reported Q3 2026 earnings of $-0.42 a share on Oct 29, 2026, beating the $-0.56 consensus estimate by 24.6%. Revenue was $353.2M against a $295.8M estimate.
BridgeBio Pharma delivered a strong third quarter of 2026, beating Wall Street expectations on both the top and bottom lines as its ATTR-CM therapy Attruby continued to gain commercial traction. Revenue of $353.17 million topped the $295.75 million consensus by 19.41% and grew 192.6% year over year, driven primarily by U.S. Attruby net product revenue of roughly $253.20 million and a $75.00 million one-time BEYONTTRA sales milestone payment from Bayer that lifted license and services revenue to $79.30 million. On a GAAP basis, which reflects that Bayer milestone as well as $26.30 million in preferred stock dividends and accretion, the company reported a loss per share of $0.42, beating the consensus estimate of $0.56 by 24.60%. The operating loss narrowed sharply to $11.60 million from $145.20 million a year ago even as commercialization spending rose. With $1.50 billion in cash, management says the company is fully funded through three anticipated product launches, including PDUFA dates for BBP-418, oral infigratinib, and encaleret falling within a seven-month window beginning November 2026.
- Attruby U.S. net product revenue up ~$145 million year over year and ~$31 million sequentially
- Growth led by the treatment-naïve segment, with rising first-line share
- $75.0 million BEYONTTRA sales milestone from Bayer recognized in license and services revenue
- $16.2 million increase in royalty revenue from BEYONTTRA sales in the EU and Japan
- SG&A up $63.2 million and R&D up $30.6 million on commercialization and late-stage development
“I'm heartened by how consistently the evidence for acoramidis keeps pointing in the same direction. This quarter we added two more large real-world comparisons to a growing body of data showing acoramidis outperforming tafamidis on the outcomes that matter most to patients: survival and hospitalizations.”
BridgeBio Pharma CEO, on the earnings call
What Is BridgeBio Pharma's Outlook?
BridgeBio expects cash, cash equivalents and marketable securities of $1.5 billion to fully fund three potential launches and expansion indications. Upcoming milestones include: - **BBP-418 (LGMD2I/R9):** PDUFA date November 27, 2026, with U.S. launch upon approval; EU MAA submission planned for the first half of 2028, based on FORTIFY Month 36 data expected late 2027/early 2028; pediatric (<12) studies to begin in the first half of 2027. - **Oral infigratinib (achondroplasia):** PDUFA date February 4, 2027; potential EU approval in the second half of 2027. - **Encaleret (ADH1):** PDUFA date May 8, 2027; potential EU approval in the second half of 2027. - **RECLAIM-HP (encaleret, chronic hypoparathyroidism):** topline data in early 2028. - **BBP-717:** IND submission in 2027. - **Acoramidis:** new data to be shared at AHA 2026.
BBIO YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $353.2M | $120.7M | +192.6% |
| Operating Income | −$11.6M | −$6.1M | +92.0% |
| Net Income | −$56.7M | −$33.6M | +69.0% |
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.